Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

In a major setback for MannKind Corporation ’s inhalable insulin therapy, Afrezza, the FDA is requiring the company to conduct two additional clinical trials of the...
Earlier this month, Eli Lilly and the German pharmaceutical Boehringer Ingelheim (BI) announced a major partnership to co-develop and co-commercialize several of their...
In late 2010, Merck announced that it had acquired SmartCells, a small Massachusetts-based company that is developing a smart insulin product aptly named SmartInsulin...
In early November, Kombiglyze, a pill combining DPP-4 inhibitor Onglyza and metformin, was approved by the FDA for type 2 diabetes. Onglyza was approved in July 2010...
Medical technology manufacturer Valeritas announced earlier this month that it received FDA clearance to market its V-Go Disposable Insulin Delivery Device, which...
In mid-November, Santarus Inc. announced the launch of Cycloset, a novel, weight-neutral, glucose-lowering drug for type 2 diabetes. Cycloset is a quick-release...
After a day of deliberation earlier this month, a recent FDA advisory committee voted 13 to 7 to recommend approval of Contrave, a novel weight-loss drug made by...
David Simmons, President and General Manager of Pfizer’s Established Products Business Unit, and Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon, shake...
Last week, in a surprise and, in our view, disappointing move, the FDA decided to not approve Bydureon, a once-weekly GLP-1 agonist, for use in the United States despite...
Just in time for the New Year, Kelly reveals good news on obesity therapies and insulin delivery devices.
Are your basal insulin settings on your pump correct? Gary Scheiner provides his expertise on how to make basal insulin adjustments, the right way.
Can Victoza help people with type 1 diabetes? See what Novo Nordisk has to say inside.
Type 1s and GLP-1s? diaTribe Editor-In-Chief Kelly Close tries Victoza and shares her remarkable results.
The FDA’s decision on Bydureon was a shocker. We break down this decision and discuss why we view it as such a disappointment.
Novo Nordisk continues to make headway in the development of Degludec and DegludecPlus, the company’s two new “next-generation” insulins. The company recently announced...
Former ADA President Dr. John Buse offers a take on the ADA and FDA and weighs in on the current regulatory environment and healthcare reform.
Obesity expert Dr. Lee Kaplan of Massachusetts General Hospital tells us how we may be able to bypass the bypass…
We recently reviewed three drug candidates for the treatment of obesity – Contrave, lorcaserin, and Qnexa. All three drugs in development: they all have been submitted...
A girl can dream, right? (...of cures and new insulins...)
A thorough review and “how-to” on the drug Symlin (Amylin’s pramlintide).

Pages